A single center, open-label, randomized, two-period, crossover, single-dose study to determine the effect of food on the bioavailability of fixed combination SPA100 (aliskiren/amlodipine 300/10 mg oral tablets) in healthy subjects.

Trial Profile

A single center, open-label, randomized, two-period, crossover, single-dose study to determine the effect of food on the bioavailability of fixed combination SPA100 (aliskiren/amlodipine 300/10 mg oral tablets) in healthy subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Sep 2016

At a glance

  • Drugs Aliskiren/amlodipine (Primary)
  • Indications Hypertension
  • Focus Pharmacokinetics
  • Sponsors Novartis
  • Most Recent Events

    • 11 Feb 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top